Primary central nervous system lymphoma: Coming or going?

Blood

Volumn 113, Issue 19, 2009, Pages 4483-4484

  DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLUORODEOXYGLUCOSE F 18;

B CELL LYMPHOMA; BONE MARROW; CANCER DIAGNOSIS; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; FOLLOW UP; HUMAN; LYMPHOMA; NOTE; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; SPINAL CORD;

EID: 70350060590     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-199877     Document Type: Note

References (3)

1. Mohile NA, DeAngelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. 2008;10:223-228.
2. McCann KJ, Ashton-Key M, Smith KA, et al. Primary CNS lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood. 2009;113:4677-4680.
3. Jahnke K, Hummel M, Korfel A, et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol. 2006;24:4754-4757. (Pubitemid 46630939)